Christopher Montemagno

Monaco, Monaco

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Beyond treatment eligibility: rethinking theranostic targets.

Beyond treatment eligibility: rethinking theranostic targets.

Journal: Frontiers in oncology

Published: July 14, 2026

The next evolution of theranostics: from target discovery to integrated precision medicine.

The next evolution of theranostics: from target discovery to integrated precision medicine.

Journal: Frontiers in medicine

Published: July 14, 2026

Integrin β1 signaling at the crossroads of cellular plasticity, the tumor microenvironment, and therapy resistance in medulloblastoma.

Integrin β1 signaling at the crossroads of cellular plasticity, the tumor microenvironment, and therapy resistance in medulloblastoma.

Journal: Frontiers in oncology

Published: July 07, 2026

Neural Innervation of Tumors: Mechanisms, Hallmarks, and Therapeutic Opportunities.

Neural Innervation of Tumors: Mechanisms, Hallmarks, and Therapeutic Opportunities.

Journal: Cancers

Published: March 09, 2026

Development and validation of a PSMA-positive triple-negative breast cancer mouse model for preclinical targeted radionuclide therapies.

Development and validation of a PSMA-positive triple-negative breast cancer mouse model for preclinical targeted radionuclide therapies.

Journal: Scientific reports

Published: October 20, 2025

Comparative theranostic efficacy of 177Lu- and 161Tb-labeled A1K2 SdAb in mesothelin-positive tumors.

Comparative theranostic efficacy of 177Lu- and 161Tb-labeled A1K2 SdAb in mesothelin-positive tumors.

Journal: European journal of nuclear medicine and molecular imaging

Published: September 17, 2025

From Seeing to Healing: The Clinical Potential of Radiotracers in Pediatric Neuro-Oncology.

From Seeing to Healing: The Clinical Potential of Radiotracers in Pediatric Neuro-Oncology.

Journal: Cancers

Published: April 23, 2025

Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy.

Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy.

Journal: Cancers

Published: March 12, 2025

Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine-Glycine-Aspartate) Strategies.

Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine-Glycine-Aspartate) Strategies.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: September 30, 2024

Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis.

Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis.

Journal: Current oncology (Toronto, Ont.)

Published: September 20, 2024

Targeting Melanin Heterogeneity in Metastatic Melanoma: A Dual-Tumour Mouse Melanoma Model.

Targeting Melanin Heterogeneity in Metastatic Melanoma: A Dual-Tumour Mouse Melanoma Model.

Journal: Experimental dermatology

Published: August 26, 2024

Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.

Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 13, 2023

Showing 1-12 of 38

Last Updated: 09/26/2026